Cathie Wood’s ARK sells Strata Critical Medical stock, buys GeneDx Holdings

ARK's April 2, 2026 daily filings show the largest trade was a sale of 26,497 Strata Critical Medical (SRTA) shares for $110,757, while ARK accumulated 2,869 GeneDx (WGS) shares across ARKK/ARKG for $187,976 and bought 12,692 Kodiak AI (KDK) shares for $91,382. Smaller trims included 200 Pinterest (PINS) shares for $3,658 and 200 Discovery Ltd (DSY) shares for $492. The activity signals continued rebalancing with a tilt toward biotech and AI exposure rather than a broad market call; impact is informational and likely limited to individual stock flows.

Analysis

ARK’s rotation into small-cap biotech and AI names is a liquidity shock more than a pure fundamental signal — when a multi-billion dollar thematic manager reallocates across low-float names it creates transient price momentum and volatility that can persist for weeks. That flow can magnify upcoming idiosyncratic catalysts (FDA filings, partnership announcements, product milestones) because dealers tighten quotes and retail momentum chases the trade; expect amplified moves around any 30–90 day company-level news.

Second-order winners are not just the direct buys but the hardware and cloud suppliers that service AI training/inference and genomic sequencing; companies with scalable margin expansion (SMCI, APP) can see secular demand lift even if the headline buys land in niche developers. Conversely, assets exposed to ad-monetization cyclicality (social platforms) can be collateral damage when active managers rotate into higher-growth, higher-volatility themes — the reallocation risk to ad revenue should be modeled over 1–3 quarters.

Tail risks: concentrated ETF flow reversals can trigger outsized drawdowns in illiquid names within days, and regulatory setbacks (clinical trial misses, FDA delays) can wipe out the premium ARK has paid. The fastest reversal would be a broad risk-off episode or a negative macro data print that forces deleveraging; absent those, expect continued two-way intraday moves with a 20–40% range potential over 3 months in the most thinly traded tickers.

Key Decisions for Investors

• Long WGS — 0.5–1.0% portfolio position via equity or 9–12 month 25–35% OTM call spread; target +40% in 6–12 months, stop -15%. Rationale: accumulation-driven momentum ahead of near-term diagnostic/regulatory catalysts; limited sizing due to small-cap liquidity risk.
• Long KDK / Short PINS pair — equal-dollar exposure (0.75% each), horizon 3–9 months. This isolates AI-autonomy upside vs ad-monetization cyclicality; target 30% net return if KDK re-rates while PINS continues to de-rate, max bilateral risk ~15% per leg.
• Hedge SRTA exposure via options — avoid naked short in cash; buy 3–6 month put spreads sized to 0.25% portfolio (buy closer-dated put / sell deeper OTM put) to monetize potential continuation of sell-pressure. Pay limited premium for asymmetric payoff: target 2:1–3:1 if a follow-through unwind occurs.
• Long SMCI (or APP) tactically — 1% portfolio, 6–12 month horizon, hedge with -0.5% Nasdaq futures to capture hardware leverage to AI demand. Expect 25–50% upside if enterprise AI capex accelerates; cap losses with 12–18% stop on the unhedged leg.